NCT04868877: A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

NCT04868877
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on prior standard first-line treatment
Exclusions: Patients with unstable, untreated, or symptomatic brain metastases- see trial for details; Patients with leptomeningeal involvement; Patients with prior treatment of a bispecific EGFR-c-MET antibody
https://ClinicalTrials.gov/show/NCT04868877

Comments are closed.

Up ↑